Assenagon Asset Management
XENE icon

Assenagon Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Assenagon Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-119,186
Closed -$5.34M – 1235
2025
Q4 		$5.34M Buy
+119,186
New +$5.01M 0.01% 626
2025
Q3 		– Sell
-436,974
Closed -$13.7M – 1278
2025
Q2 		$13.7M Buy
436,974
+195,768
+81% +$6.39M 0.02% 416
2025
Q1 		$8.09M Buy
241,206
+2,684
+1% +$102K 0.01% 459
2024
Q4 		$9.35M Buy
238,522
+26,235
+12% +$1.08M 0.02% 533
2024
Q3 		$8.36M Buy
212,287
+138,685
+188% +$5.59M 0.02% 578
2024
Q2 		$2.87M Sell
73,602
-113,004
-61% -$4.52M 0.01% 792
2024
Q1 		$8.03M Buy
186,606
+86,875
+87% +$4M 0.02% 485
2023
Q4 		$4.59M Sell
99,731
-47,962
-32% -$1.69M 0.01% 662
2023
Q3 		$5.05M Buy
+147,693
New +$5.52M 0.02% 575

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Assenagon Asset Management's XENE Position: Q1 2026 in Review

Assenagon Asset Management sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 119,186 shares — an estimated $5.34M sold.

Assenagon Asset Management first reported a position in XENE in Q3 2023 and held it in 9 quarters. The position peaked at $13.7M in Q2 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Assenagon Asset Management reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Assenagon Asset Management sold 119,186 Xenon Pharmaceuticals shares in Q1 2026, an estimated $5.34M.
  • Assenagon Asset Management first reported a position in Xenon Pharmaceuticals in Q3 2023 and held it in 9 quarters.
  • Assenagon Asset Management's Xenon Pharmaceuticals position peaked at $13.7M in Q2 2025.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Assenagon Asset Management's 13F filing for Q1 2026, filed 20 Apr 2026.